Table 1.

Clinical characteristics of patients treated on NCT #04663347.

Patient N.	Histology	Setting	Prior therapies	Best response	Last follow-up
					Treatment	Response	Status
1	DLBCL, non-GCB	ND		CR	Completed	CR	A
2	DLBCL, non-GCB	ND		CR	Completed	CR	A
3	DLBCL (tFL), non-GCB	ND		CR	Completed	CR	A
4	DLBCL, non-GCB	ND		CR	Completed	CR	A
5	DLBCL, GCB	ND		CR	Completed	CR	A
6	DLBCL (tFL), GCB	ND		CR	Completed	CR	A
7	DLBCL	ND		CR	Completed	CR	A
8	DLBCL	RR	R-EPOCH; R-ICE; CAR-T	PR	Completed	PD	D
9	DLBCL, non-GCB	RR	R-CHOP/R-ICE; R-DHAX; CAR-T	PR	Completed	PD	D
10	FL, G1–2	ND		CR	Completed	CR	A
11	FL, G1–2	ND		CR	Completed	CR	A
12	FL, G3A	ND		CR	Ongoing	CR	A
13	FL, G1–2	RR	R-CHOP	CR	Completed	CR	A
14	FL, G1–2	RR	R-CHOP	CR	Ongoing	CR	A
15	FL, G1–2	RR	R-CHOP; R-len	CR	Ongoing	CR	A
16	FL, G1–2	RR	BR	CR	Completed	PD	A
17	FL, G3A	RR	R-CHOP	CR	Completed	CR	A
18	FL, G3A	RR	O-CVP; O-CEOP; RT	CR	Completed	CR	A
19	FL, G1–2 (prior DLBCL)	RR	R-CHP-polatuzumab (for DLBCL)	CR	Completed	CR	A
20	FL, G1–2 (prior DLBCL)	RR	R-EPOCH, R-GemOx, CAR-T, R-DHAX, O-len, other*	PD	Completed	PD	D
21	FL, G1–2	RR	O-CHOP	CR	Ongoing	CR	A
22	FL, G1–2	RR	O-CHOP, BR-HDT-ASCS	CR	Ongoing	CR	A

Study arms: 1, epcor-R-CHOP; 5, epcor-GemOx; 6 adn 2b, epcor_R-len.

^*pembrolizumab-entinostat, zanubrutinib-zandelisib both as part of a clinical trial. Abbreviations: DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B; (t)FL, (transformed) follicular lymphoma; G, grade; ND, newly diagnosed; RR, relapsed or refractory; R, rituximab; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; CAR-T, chimeric antigen receptor cell therapy; CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; len, lenalidomide DHAX, dexamethasone, cytarabine, oxaliplatin, B, bendamustine; CVP, cyclophosphamide, vincristine, prednisone; GemOx, gemcitabine, oxaliplatin; HDT-ASCS, high-dose therapy adn autologous stem cell support; epcor, epcoritamab; CR, complete response; PR, partial response; PD, progressive disease; A, alive, D, dead.